Q2 2025 CVRx Inc Earnings Call Transcript
Key Points
- CVRx Inc (CVRX) reported a 15% increase in total revenue for Q2 2025, reaching $13.6 million, indicating strong growth compared to the same quarter last year.
- The company expanded its network to 240 active implanting centers in the US, up from 227 in Q1 2025, showcasing successful expansion efforts.
- CVRx Inc (CVRX) has made significant progress in its sales force transformation, with turnover returning to normal and a focus on optimizing onboarding and training.
- Reimbursement improvements, including the transition to Category 1 CPT codes in January 2026, are expected to enhance commercial efforts and reduce barriers to adoption.
- The company's clinical strategy is advancing, with ongoing efforts to generate robust clinical evidence to support Barostim's adoption as a standard of care.
- Despite revenue growth, CVRx Inc (CVRX) reported a net loss of $14.7 million for Q2 2025, slightly higher than the $14 million loss in the prior year period.
- The company is still in the process of getting new territory managers up to speed, with more than 35% hired since January 2025, which may impact short-term productivity.
- SG&A expenses increased by 11% to $23.4 million in Q2 2025, driven by higher compensation and travel expenses, which could pressure profitability.
- Interest expense increased due to higher levels of borrowings under the term loan agreement, impacting financial performance.
- The guidance for full-year 2025 revenue was narrowed, reflecting uncertainties in the pace of productivity improvements among new sales hires.
Good afternoon, ladies and gentlemen. Welcome to today's CVRx Q2 2025 earnings call. (Operator Instructions) Also, today's call is being recorded. (Operator Instructions) Now at this time, I'd like to turn things over to Mr. Mike Vallie with ICR.
Mr. Vallie, please go ahead, sir.
Good afternoon. Thank you for joining us today for CVRx's second-quarter 2025 earnings conference call. Joining me on today's call are the company's President and Chief Executive Officer, Kevin Hykes; and Chief Financial Officer, Jared O'sheim. The remarks today will contain forward-looking statements, including statements about financial guidance. These statements are based on plans and expectations as of today, which may change over time.
In addition, actual results could differ materially due to a number of risks and uncertainties, including those identified in the earnings release issued prior to this call and in the company's SEC filings. I would now like to turn the call over to CVRx's President and Chief Executive
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
